La cadena de opciones muestra datos clave de las opciones de acciones de TELA Bio a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para TELA Bio..

TELA Bio (NASDAQ:TELA) Bolsa, Cadena de Opciones

TELA Bio

TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.

TELA Bio Inc

Teladoc Health Inc

Dear Esteemed Shareholders,
I am pleased to provide you with significant updates regarding the leadership of DSS, Inc. and to outline the strategic direction we are pursuing as a Company.
It is with great honor that I announce my appointment as Interim Chief Executive Officer of DSS, Inc., effective August 23, 2024. With over 25 years of experience in leadership roles across diverse sectors—ranging from Chief Operating Officer of DSS to President at Premier Packaging Corporation, CEO and Director of DSS Biohealth Holdings, and Chief Business Officer at Impact Biomedical, Inc.—I am eager to guide DSS through its next phase of growth, operational refinement, and market leadership.
A Clear Vision for the Future
As we embark on this new chapter, my immediate focus is to optimize operational efficiencies, realign resources, and position DSS, Inc. for sustainable long-term growth. To this end, we have already initiated a series of decisive actions, the results of which are reflected in our most recent earnings report. Below, I have highlighted our key accomplishments and prioritized initiatives moving forward:
Q3 Financial Performance Highlights – Strengthening Our Business Model
<ul>
<li>Immediate executive action and swift decision making, allowed for DSS to report operating loss for the nine months ended September 30, 2024 had decreased by approximately $1.3 million (8%) compared to the same period in 2023, with a $0.4 million (8%) reduction for the three months ended September 30, 2024, relative to the same period in 2023.</li>
<li>The net loss for the nine months ended September 30, 2024, declined by $17.3 million (52%) year-over-year, with a reduction of $1.0 million (15%) for the three-month period.</li>
<li>Cash flow from operations showed marked improvement, increasing by $11.8 million (56%) for the nine months ended September 30, 2024. Our net cash position strengthened from $6.9 million to $11.6 million.</li>
<li>The successful spin-off of Impact BioMedical, Inc. in September has positioned both entities for future growth within their respective markets.</li>
</ul>
Driving Revenue Growth and Operational Excellence
<ul>
<li>Expanding High-Impact Business Lines: We are focusing on the strategic expansion of promising business units, such as Premier Packaging, to fuel continued growth.</li>
<li>Exploring Untapped Markets: Our commitment to identifying and investing in high-growth markets will drive the creation of scalable and recurring revenue streams.</li>
<li>Enhancing Accountability: We will institute robust, metrics-driven accountability systems across business units to ensure consistent execution on high-priority opportunities. &nbsp;</li>
</ul>
Eliminating Inefficiencies and Optimizing Cost Structure
<ul>
<li>Comprehensive Review and Streamlining: A thorough evaluation of all business units is underway to identify underperforming segments. We will restructure, streamline, or divest from non-core areas to reinforce our primary strengths.</li>
<li>Process and Technology Optimization: New operational tools and processes will be introduced to reduce inefficiencies, eliminate waste, and increase productivity in procurement, production, and logistics.</li>
<li>Targeted Cost Reduction: Our goal is to reduce costs by 15-20% in the upcoming fiscal year, significantly enhancing profitability and reinforcing our financial stability. &nbsp;</li>
</ul>
Pioneering Innovation for Competitive Advantage
<ul>
<li>Advancing R&amp;D Initiatives: We will leverage our research and development capabilities to drive cutting-edge solutions in emerging sectors, such as biomedical technologies and sustainable packaging.</li>
<li>Cultivating Strategic Partnerships: We are actively forging alliances with key industry players to accelerate the market introduction of innovative products and solutions.</li>
<li>Pilot Program Launches: We plan to deploy targeted pilot programs in select regions or sectors to validate new initiatives, enabling us to scale these innovations company-wide. &nbsp;</li>
</ul>
Maximizing Shareholder Value with Discipline and Transparency
<ul>
<li>Disciplined Financial Stewardship: We remain unwavering in our focus on delivering consistent growth, profitability, and returns for our shareholders.</li>
<li>Commitment to Transparency: You can expect regular, transparent updates on our progress, milestones, and strategic objectives to ensure you remain well-informed at every stage.</li>
<li>Exploring Shareholder Rewards: We are actively exploring initiatives designed to directly reward our shareholders for their continued trust and support. &nbsp;</li>
</ul>
Leadership Transition
This moment marks a pivotal turning point for DSS, Inc. With a clear vision, a focused strategy, and an unwavering commitment to execution, we are poised to unlock new opportunities and create sustainable, long-term value for our shareholders.
Thank you for your ongoing support and confidence in DSS, Inc. I look forward to keeping you informed on our progress in the months ahead. Should you require additional information, please do not hesitate to reach out to our Investor Relations team.
Sincerely,
Jason Grady Interim Chief Executive Officer DSS, Inc.

News

Guidance

DSS Interim CEO Issues Letter To Shareholders

JMP Securities analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) with a Market Outperform and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

ANTX

JMP Securities Reiterates Market Outperform on AN2 Therapeutics, Maintains $5 Price Target

WIIM

CRON

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

MSOS

SNDL

TLRY

Shares of cannabis-linked stocks are trading lower as traders evaluate tariff risks.

<a href="https://www.benzinga.com/etfs">YieldMax has introduced</a> the YieldMax CVNA Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNY#NYSE">CVNY</a>), which will allow investors to generate income while enjoying exposure to the stock price movements of Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>). 
The <a href="https://www.benzinga.com/etfs">actively managed fund</a> follows a synthetic covered call strategy, and operates with a net expense ratio of 0.99%.
The fund achieves synthetic long exposure to Carvana by buying call options and selling put options simultaneously. It primarily trades standardized exchange-traded or FLEX options, with durations ranging from one to six months. At times, the fund managers may use credit call spreads instead of standard call options based on market conditions. 
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/01/43009701/new-yieldmax-etf-targets-crypto-tech-sectors-with-income-strategy">New YieldMax ETF Targets Crypto, Tech Sectors With Income Strategy</a>
The ETF also holds short-term U.S. Treasury securities as collateral and for additional income generation.
Carvana's stock has rebounded significantly, up around a whopping 465% in the past year, and the new ETF offers investors a way to take advantage of this momentum while benefiting from its income-focused strategy. So, investors can capitalize on the online used car retailer's price fluctuations without directly owning the stock.
With the CVNA Option Income Strategy ETF launch, YieldMax now has over 70 investment <a href="https://www.morningstar.com/asset-management-companies/yieldmax-etfs-BN00000OIP">vehicles</a>, with 40 ETFs in the U.S. that specialize in single-stock option strategies. The firm collectively manages more than $7.35 billion in assets, which speaks of strong investor interest. YieldMax&#8217;s asset growth rate on a trailing twelve month basis is at 489.65%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43403716/3-u-s-auto-etfs-caught-in-the-crosshairs-as-trump-announces-25-tariff-on-mexican-imports">3 U.S. Auto ETFs Caught In The Crosshairs As Trump Announces 25% Tariff On Mexican Imports</a></li>
</ul>
Photo: Courtesy of Carvana

CVNA

Tidal Trust II YieldMax CVNA Option Income Strategy ETF

CVNY

YieldMax Rolls Out New ETF For Investors To Tap Into Carvana's Rally And Generate Income

Dividends

FBIZ

First Business Bank Increases Dividend From $0.25 To $0.29

Standard Chartered&#8216;s Head of Digital Assets Research Geoffrey Kendrick on Monday advised against buying the dip in cryptocurrencies until outright back-end <a href="https://www.benzinga.com/25/01/42939374/as-bond-yields-near-the-crucial-5-mark-last-seen-briefly-in-2023-and-global-financial-crisis-this-analyst-says-market-appears-to-be-overreacting">U.S. Treasury yields come lower</a>.
What Happened: In a note to Benzinga, Kendrick stated that the current sell-off differs significantly from the previous one.
While last week&#8217;s decline, driven by developments around <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43248978/could-bitcoin-see-a-deeper-dip-on-the-deepseek-ai-shock">China&#8217;s DeepSeek</a>, was a buying opportunity, today&#8217;s market downturn stems from newly imposed U.S. tariffs on Canada and Mexico, fueling inflation concerns and dragging down risk assets.
Kendrick explained that the tariffs are having a &#8220;outright negative&#8221; effect on digital asset prices by increasing U.S. inflation expectations. 
He highlighted a 10 basis point increase in 2-year inflation expectations since Friday, further compounding the pressure on risk assets.
&#8220;The bigger/next question for me is whether and/or when growth fears outweigh inflation fears,&#8221; he said, explaining that the market needs to see nominal yields at the longer end of the U.S. Treasury curve come down, which would signal growth concerns are taking precedence over inflation.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43430801/exclusive-anthony-scaramucci-warns-donald-trumps-crypto-promises-may-be-a-mirage">EXCLUSIVE: Anthony Scaramucci Warns Donald Trump&#8217;s Crypto Promises May Be A &#8216;Mirage&#8217;</a>
Why It Matters: Major cryptocurrencies have experienced <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43432142/dogecoin-shiba-inu-crater-13-as-bitcoin-takes-a-tariff-beating">dramatic price drops</a> early Monday morning.
Within the last 24 hours, top tokens have slumped by over 25%, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) down approximately 7% and Ether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) plummeting by 20% in morning trade. 
Other major tokens including Ripple&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Cardano's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) have fallen by more than 25% reversing all the gains since December. 
This sharp downturn has wiped out gains made since the start of December, reaching levels not seen since early November before the U.S. election. In fact, many major tokens have fallen between 40 and 50% in the past month alone.
The rapid decrease in price triggered significant liquidations, with total liquidations across exchanges exceeding $2.2 billion, the highest so far this year and among the most substantial in the past year. 
A single liquidation order on Binance, involving a $25 million Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>)-margined ETH trade, suggests the severity of the market downturn.
Kendrick suggests that while digital assets will eventually benefit from lower real yields and higher inflation expectations in the US treasury market, it will take lower outright nominal yields to solidify that. 
He advised that investors should wait until there are explicit signs of growth fears dominating inflation concerns. 
Until then, he believes that the market may be in for a &#8220;choppy few days where the $90,000 level in BTC is again at risk."
Kendrick warns that the current market conditions are not conducive to immediately buying the dip, given the potential for further volatility until there is evidence that growth fears are <a href="https://www.benzinga.com/news/econ-s/25/01/43396354/inflation-rises-again-may-be-end-of-the-road-for-interest-rate-cuts-expert-says">outpacing inflation fears</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43404802/grayscale-seeks-sec-approval-to-convert-xrp-trust-into-exchange-traded-fund">Grayscale Seeks SEC Approval To Convert XRP Trust Into Exchange-Traded Fund</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$DOGE

$ETH

$USDT

$XRP

Don't Buy The Dip On Bitcoin, Ethereum, XRP Yet, Standard Chartered Warns

B. Riley Securities analyst Craig Ellis maintains GCT Semiconductor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) with a Buy and lowers the price target from $8 to $5.

GCTS

B. Riley Securities Maintains Buy on GCT Semiconductor Hldgs, Lowers Price Target to $5

EYEN

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

PROC

Procaps Group Receives Nasdaq Delisting Notice

&nbsp;Shares of retail stocks are trading lower as investors evaluate U.S. tariff risks which may negatively impact industry revenues.&nbsp;
&nbsp;Shares of retail stocks are trading lower as investors evaluate U.S. tariff risks which may negatively impact industry revenues.&nbsp;

BARK

BGFV

BURL

CANG

DLTR

FIVE

LULU

MUSA

PLCE

REAL

SFIX

SHOO

ULTA

Shares of retail and apparel stocks are trading lower as investors evaluate U.S. tariff risks which may hinder industry sales.

Earnings

Coffee Holding FY24 EPS $0.39 Up From $(0.15) YoY; Net Sales Up 15% YoY

B. Riley Securities analyst Josh Nichols reiterates Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) with a Buy and lowers the price target from $37 to $32.5.

GNTX

B. Riley Securities Reiterates Buy on Gentex, Lowers Price Target to $32.5

Keybanc analyst Justin Patterson upgrades Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) from Sector Weight to Overweight and announces $100 price target.

Upgrades

Keybanc Upgrades Zillow Gr to Overweight, Announces $100 Price Target

Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) disclosed several transactions and partnerships at the Baker Hughes <a target="_blank" href="https://www.benzinga.com/quote/BKR" rel="noreferrer noopener">2025 Annual Meeting in Florence</a>.
ExxonMobil Contract: Baker Hughes secured a contract from Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) Guyana to supply specialty chemicals and services for the Uaru and Whiptail offshore <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43426683/baker-hughes-secures-major-chemicals-award-from-exxonmobil-guyana-for-fpsos" rel="noreferrer noopener">developments in the Stabroek Block</a>.
Uaru and Whiptail are ExxonMobil Guyana&#8217;s fifth and sixth projects, featuring up to 20 drill centers and 92 wells.
Each FPSO will have a capacity of 250,000 barrels per day, raising the country's total production capacity to 1.3 million barrels per day.
The multi-year contract covers topsides, subsea, water injection, and utility chemicals for the Errea Wittu and Jaguar FPSOs, set to begin production in 2026 and 2027, respectively.
Hanwha Partnership: Baker Hughes inked a joint Development and Collaboration Agreement (JDCA) with Hanwha Power Systems and Hanwha Ocean to develop a small-size <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43426721/baker-hughes-and-hanwha-announce-partnership-to-develop-small-size-ammonia-turbines" rel="noreferrer noopener">turbine for ammonia applications</a>.
The turbine will combine Baker Hughes&#8217; gas turbine technology with Hanwha&#8217;s ammonia combustion system.
Baker and Hanwha plan to complete full engine testing with ammonia by the end of 2027, after which the ~16MW turbine will be available for commercial orders.
Argent LNG Contract: The company has been chosen by Argent LNG as the liquefaction solution and services provider for its proposed LNG <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43427007/argent-lng-selects-baker-hughes-as-technology-provider-strengthening-project" rel="noreferrer noopener">export facility in Port Fourchon, Louisiana</a>.
Baker Hughes will supply liquefaction technology, power generation equipment, and gas compression systems for the facility, which aims to produce approximately 24 MTPA of LNG.
Last month, Baker Hughes reported fourth-quarter adjusted EPS&nbsp;of $0.70, beating the consensus of $0.63 and sales&nbsp;of $7.36 billion, exceeding <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43356061/baker-hughes-announces-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">the street view of&nbsp;$7.08 billion</a>.
Investors can gain exposure to the stock via iShares U.S. Oil Equipment &amp; Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEZ#NYSE">IEZ</a>) and&nbsp;VanEck Oil Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIH#NYSE">OIH</a>).
Price Action: BKR shares are up 0.39% at $46.36 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43427872" target="_blank" rel="noreferrer noopener">Dow Dips Over 300 Points As Trump Imposes Tariffs On Canada, Mexico, And China: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Contracts

iShares Dow Jones US Oil Equipment & Services Index Fund

Baker Hughes Lands ExxonMobil Guyana Deal, Partners With Hanwha On Ammonia Turbines

Keybanc analyst Bradley Thomas maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Overweight and raises the price target from $66 to $70.

Keybanc Maintains Overweight on Tempur Sealy Intl, Raises Price Target to $70

Keybanc analyst Paul Knight maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Overweight and raises the price target from $132 to $145.

RVTY

Keybanc Maintains Overweight on Revvity, Raises Price Target to $145

Keybanc analyst Steve Barger maintains RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) with a Overweight and raises the price target from $375 to $395.

Keybanc Maintains Overweight on RBC Bearings, Raises Price Target to $395

Unusual Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) has announced the signing of a binding agreement to acquire of Aloft Technologies, Inc. (<a href="https://pr.report/6pai">https://www.aloft.ai/</a>), the leading FAA-approved provider of unmanned aerial system (UAS) services to enterprise, public safety, and government customers. The acquisition is almost all in stock, valued at $14.5M.
The proposed acquisition brings together companies that share commitment to strengthening the U.S. drone industry. Aloft Technologies has long been recognized as the leader in the drone fleet and airspace management sector, powering more than 70% of all FAA-approved Low Altitude Authorization and Notification Capability (LAANC) airspace authorizations in the United States. Aloft has provided more than more than 1.6 million authorizations in total, with 400,000 authorizations provided in 2024.
Aloft has been able to leverage the data collected through millions of safe flights and airspace interactions to launch <a href="https://pr.report/6paj">Air Boss</a>, their new real-time UAS air traffic management (UTM) software. With the FAA <a href="https://pr.report/6pak">forecasting</a> more than 3 million drones in the airspace by 2028, outnumbering traditional aircraft more than 10-to-1, the coordination and integration of all aircraft is critical to national security and the national economy.
The closing of the acquisition is contingent on satisfaction of customary closing conditions by the parties including Aloft obtaining stockholder approval, the delivery by Aloft of its audited financials acceptable to Unusual Machines, the receipt of certain third party consents and the holders of no more than 10% of Aloft common stock have asserted appraisal rights.

UMAC

Unusual Machines Enters Into Definite Agreement To Acquire Drone Software Company Aloft Technologies; The Acquisition Is Almost All In Stock, Valued At $14.5M

Keybanc analyst Aleksey Yefremov maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Overweight and lowers the price target from $50 to $40.

Keybanc Maintains Overweight on Olin, Lowers Price Target to $40

Buybacks

Axis Capital Enters $200M Stock Repurchase Agreement

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on TELA Bio (TELA – Research Report), with a price target of $8...

Lake Street Reaffirms Their Buy Rating on TELA Bio (TELA)

The company said, "Reiterated full year 2024 revenue guidance of $74.5 million to $76.5 million, representing 27% to 31% year-over-year growth. Imp...

Tela Bio backs FY24 revenue view $74.5M-$76.5M, consensus $74.4M

Reports Q3 revenue $18.96M, consensus $18.85M. "Third quarter revenue of $19 million was the highest in TELA Bio's (TELA) history and indicates a h...

Tela Bio reports Q3 EPS (42c), consensus (40c)

The latest update is out from TELA Bio ( ($TELA) ). TELA Bio reported a record $19 million in third-quarter revenue for 2024, marking a 26% increas...

TELA Bio Achieves Record Q3 Revenue Growth in 2024

TELA Bio GAAP EPS of -$0.42 beats by $0.03, revenue of $18.96M beats by $0.11M

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Tela Bio (TELA) to $5 from $8 and keeps an Overweight rating on the shares fo...

Tela Bio price target lowered to $5 from $8 at Piper Sandler

TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript

David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on TELA Bio (TELA – Research Report). The associated price target is $12.0...

TELA Bio's Strong Financial Performance and Strategic Positioning Justify Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keros Therapeutics (KROS – Research Report), Ceribel...

Analysts Are Bullish on These Healthcare Stocks: Keros Therapeutics (KROS), Ceribell, Inc. (CBLL)

Caitlin Cronin, an analyst from Canaccord Genuity, maintained the Buy rating on TELA Bio (TELA – Research Report). The associated price target rema...

TELA Bio Set for Growth with Strategic Enhancements and Financial Improvements

CBLL

KROS

TELA

Press Releases

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance

TELA Bio to Announce Third Quarter 2024 Financial Results

Markets

TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Comments

TELA Bio

TELA Bio (TELA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL